2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice.
Javier Rodriguez-CarrioAgata BurskaPhilip Gerard ConaghanWillem A DikRobert BiesenMaija-Leena ElorantaGiulio CavalliMarianne VisserDimitrios T BoumpasGeorge BertsiasMarie Wahren-HerleniusJan RehwinkelMarie-Louise FrémondMary K CrowLars RönnblomMarjan A VersnelEdward M VitalPublished in: Annals of the rheumatic diseases (2023)
IFN-I assays have a high potential for implementation in the clinical management of RMDs. Uptake of these PtC will facilitate the progress of IFN-I assays into clinical practice and may be also of interest beyond rheumatology.